002252 上海莱士
未开盘 04-28 09:30:00
资讯
新帖
简况
上海莱士：血液制品中罕见病药物仍适用3%简易征收
证券之星 · 04-24
上海莱士：血液制品中罕见病药物仍适用3%简易征收
上海莱士：其余回购股份已分别于2023年11月、2024年8月注销完成
证券之星 · 04-15
上海莱士：其余回购股份已分别于2023年11月、2024年8月注销完成
上海莱士拓浆难拓利背后：扩张边际效益递减 商誉、现金流与竞争压力层层叠加
新浪证券 · 04-09
上海莱士拓浆难拓利背后：扩张边际效益递减 商誉、现金流与竞争压力层层叠加
股市必读：上海莱士(002252)股东户数11.36万户，较上期增加0.09%
证券之星 · 04-07
股市必读：上海莱士(002252)股东户数11.36万户，较上期增加0.09%
“换血葆青春”谣言击中上海莱士：谁在消费A股“血王”？
市场资讯 · 04-03
“换血葆青春”谣言击中上海莱士：谁在消费A股“血王”？
上海莱士：受行业政策影响主营业务收入第四季度出现阶段性波动
证券之星 · 04-03
上海莱士：受行业政策影响主营业务收入第四季度出现阶段性波动
“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？
华夏时报网 · 03-29
“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？
上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%
证券之星 · 03-27
上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%
上海莱士：2026年4月29日召开2025年度股东会
证券日报网 · 03-26
上海莱士：2026年4月29日召开2025年度股东会
上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%
智通财经 · 03-26
上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%
股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%
证券之星 · 03-25
股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%
常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目
智通财经 · 03-24
常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目
上海莱士：公司研发创新的SR604注射液已进入临床试验阶段
每日经济新闻 · 03-16
上海莱士：公司研发创新的SR604注射液已进入临床试验阶段
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%
证券之星 · 03-11
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%
上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素
证券之星 · 03-10
上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素
上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证
证券之星 · 03-09
上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证
上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用
证券之星 · 03-04
上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用
上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%
证券之星 · 03-02
上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%
上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%
证券之星 · 02-02
上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%
上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%
证券之星 · 01-30
上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%
加载更多
公司概况
公司名称：
上海莱士血液制品股份有限公司
所属行业：
医药制造业
上市日期：
2008-06-23
主营业务：
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。
发行价格：
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":5.47,"timestamp":1777338639000,"preClose":5.47,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":6634000000,"shares":6638000000,"eps":0.1448,"marketStatus":"未开盘","change":0,"latestTime":"04-28 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.1448,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"adjPreClose":5.47,"symbolType":"stock","openAndCloseTimeList":[[1777339800000,1777347000000],[1777352400000,1777359600000]],"highLimit":6.02,"lowLimit":4.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637984837,"isCdr":false,"pbRate":1.12,"roa":"--","peRate":37.776243,"roe":"4.9%","epsLYR":0.24,"committee":0,"marketValue":36310000000,"turnoverRate":0,"status":2,"floatMarketCap":36287000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2629896440","title":"上海莱士：血液制品中罕见病药物仍适用3%简易征收","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896440","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896440?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:33","pubTimestamp":1777001611,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，行业今年增值税调整，会否对业绩有很大影响？展开具体说说上海莱士回复：您好！感谢您对我公司的关心和支持！依据国家增值税新政，血液制品中的罕见病药物仍适用3%简易征收，其他血液制品业务不再适用3%简易征收，该调整属于行业统一政策。上述政策的调整，对行业及公司有一定影响。公司将通过优化采购管理、增强进项抵扣管理力度等合规方式降低政策变动带来的影响。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400034953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0196","002252","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627282416","title":"上海莱士：其余回购股份已分别于2023年11月、2024年8月注销完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2627282416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627282416?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:52","pubTimestamp":1776257529,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士04月14日在投资者关系平台上答复投资者关心的问题。除部分回购股份用于公司2023年推出的第一期员工持股计划外；其余回购股份已分别于2023年11月、2024年8月注销完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500040973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0028","BK0046","002252","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901484","title":"上海莱士拓浆难拓利背后：扩张边际效益递减 商誉、现金流与竞争压力层层叠加","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901484","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626901484?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:31","pubTimestamp":1775719860,"startTime":"0","endTime":"0","summary":" 近日，上海莱士披露2025年年度报告。报告期内，公司“拓浆”战略稳步推进，采浆量突破2000吨、浆站布局增至55家，浆源规模持续扩大，浆源核心壁垒的布局稳步推进。 然而，规模层面的增长，并未转化为经营端的实际效益，反而迎来核心指标的全面承压，公司营收、归母净利润双双大幅下滑，经营活动现金流持续净流出，核心产品毛利率全线走低，叠加资产减值损失冲击，企业盈利水平明显缩水。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-09/doc-inhtwtfe0984727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","002252","BK0188","159399","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625864609","title":"股市必读：上海莱士(002252)股东户数11.36万户，较上期增加0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625864609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625864609?lang=zh_cn&edition=full","pubTime":"2026-04-07 03:36","pubTimestamp":1775504173,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，上海莱士报收于5.77元，下跌2.2%，换手率0.4%，成交量26.54万手，成交额1.54亿元。交易信息汇总资金流向4月3日主力资金净流出391.66万元，占总成交额2.54%；游资资金净流入1173.55万元，占总成交额7.63%；散户资金净流出781.89万元，占总成交额5.08%。股本股东变化股东户数变动近日上海莱士披露，截至2026年3月31日公司股东户数为11.36万户，较3月20日增加100.0户，增幅为0.09%。户均持股数量由上期的5.85万股减少至5.84万股，户均持股市值为34.01万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","002252","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624165118","title":"“换血葆青春”谣言击中上海莱士：谁在消费A股“血王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624165118","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624165118?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:05","pubTimestamp":1775210700,"startTime":"0","endTime":"0","summary":" 血制品龙头无辜“躺枪”。 浙大城市学院副教授、中国法律咨询中心民商事专委会原副秘书长林先平认为，公众因“盈康一生”生态品牌将旗下企业视为一体，导致与“换血”谣言关键词重合的上海莱士无辜受累。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-04-03/doc-inhtfkwu0279246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","002252","BK0046","399300","BK0196","BK0188","159982","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658610","title":"上海莱士：受行业政策影响主营业务收入第四季度出现阶段性波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658610","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658610?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:04","pubTimestamp":1775199861,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司主营业务收入在第四季度出现异常下滑，是什么原因？能否做一下解释？上海莱士回复：您好！感谢您对我公司的关心和支持！受血液制品地方集采、医保控费及DRG/DIP支付改革等行业政策影响，叠加市场竞争环境变化、渠道库存阶段性调整等因素，公司主营业务收入在第四季度出现阶段性波动。公司将持续聚焦主业经营，扎实推进拓浆、脱浆战略，不断提升经营质量与盈利水平。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","002252","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623331355","title":"“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623331355","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623331355?lang=zh_cn&edition=full","pubTime":"2026-03-29 08:43","pubTimestamp":1774744998,"startTime":"0","endTime":"0","summary":"中信证券重仓股情况近期，券商“一哥”中信证券(600030.SH)正式披露2025年年度报告，整体经营稳健且核心业务多点突破。2025年公司实现营业收入748.54亿元，同比增长28.79%；实现归属于母公司股东净利润300.76亿元，同比增长38.58%，创历史最佳业绩表现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603293687921846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603293687921846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0044","BK0214","LU1997245177.USD","BK0183","BK0182","BK0235","BK0012","LU2148510915.USD","LU0405327494.USD","BK0046","LU1580142542.USD","000401","LU2495084118.USD","LU1064130708.USD","BK0077","600030","BK0010","LU1328615791.USD","LU1997244956.HKD","BK0088","BK0188","LU1655091616.SGD","BK0028","600529","LU2289578879.USD","000789","000822","002252","BK0251","BK0242","LU1781817850.SGD","BK0172","BK0229","LU0405327148.USD","BK0196","BK0239","BK0185","002981","BK0276","600711","LU1255011170.USD","LU1997245094.SGD","LU1064131003.USD","300595","BK0025","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622284259","title":"上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622284259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622284259?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:33","pubTimestamp":1774604038,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，上海莱士报收于5.85元，较前一交易日上涨0.34%，最新总市值为388.32亿元。该股当日开盘5.77元，最高5.87元，最低5.75元，成交额达1.65亿元，换手率为0.43%。上海莱士于近日披露《2025年年度报告》。报告显示，2025年末公司总资产为37,781,306,856.26元，归属于上市公司股东的净资产为32,456,025,360.59元。基本每股收益0.24元，稀释每股收益0.24元，加权平均净资产收益率4.90%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700036784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0188","BK0046","BK0196","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622869914","title":"上海莱士：2026年4月29日召开2025年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2622869914","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622869914?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:09","pubTimestamp":1774534140,"startTime":"0","endTime":"0","summary":"证券日报网讯3月26日，上海莱士发布公告称，公司将于2026年4月29日召开2025年度股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-26/doc-inhsiusr8818207.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-26/doc-inhsiusr8818207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0028","BK0188","BK0046","002252","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622686559","title":"上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622686559","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622686559?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:43","pubTimestamp":1774532616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士(002252.SZ)发布2025年年度报告，报告期内，公司实现营业收入73.48亿元，同比下降10.13%。实现归属于上市公司股东的净利润15.77亿元，同比下降28.10%。实现归属于上市公司股东的扣除非经常性损益的净利润15.6亿元，同比下降24.25%。基本每股收益为0.24元。拟向全体股东每10 股派发现金红利0.33元(含税)。截至2025年12月末，公司总资产377.81亿元，较上年末增加 12.34%;归属于上市公司股东的净资产324.56亿元，较上年末增加1.66%;资金储备28.4亿元，流动性充足，资产结构稳健。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622097101","title":"股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622097101","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622097101?lang=zh_cn&edition=full","pubTime":"2026-03-25 02:24","pubTimestamp":1774376653,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，上海莱士报收于5.83元，上涨1.39%，换手率0.39%，成交量25.96万手，成交额1.51亿元。交易信息汇总资金流向3月24日主力资金净流入373.26万元；游资资金净流出680.73万元；散户资金净流入307.46万元。股本股东变化股东户数变动近日上海莱士披露，截至2026年3月20日公司股东户数为11.35万户，较3月10日减少557.0户，减幅为0.49%。户均持股数量由上期的5.82万股增加至5.85万股，户均持股市值为35.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","BK0028","BK0239","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621054611","title":"常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054611","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621054611?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:51","pubTimestamp":1774338691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，常铝股份(002160.SZ)发布公告，近日，公司全资子公司上海朗脉洁净技术股份有限公司(以下简称“上海朗脉”)收到《中标通知书》，确定上海朗脉为上海莱士血液制品股份有限公司产能扩建工程机电、净化安装项目(专业分包)的中标单位，本次中标项目的中标金额合计为1.835亿元，占上海朗脉2024年度经审计营业收入的20.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","002160","BK0239","002252","BK0233","BK0076","BK0188","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619365054","title":"上海莱士：公司研发创新的SR604注射液已进入临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2619365054","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619365054?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:55","pubTimestamp":1773633300,"startTime":"0","endTime":"0","summary":"公司将加快推进各阶段临床试验等工作，力争早日实现产品上市。除“SR604”外，公司也正在推进其他全球首创新靶点新机制的抗体药物研发。公司“脱浆”战略着眼于创新突破，在夯实血液制品研发基础的同时，积极向生物制药高附加值领域拓展。前述“SR604”产品、其他研发管线布局以及现有产品新适应扩展是公司落实“拓浆”、“脱浆”战略的重要工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhreeew9826364.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhreeew9826364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK0188","BK0239","002252","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618950517","title":"股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618950517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618950517?lang=zh_cn&edition=full","pubTime":"2026-03-11 01:15","pubTimestamp":1773162911,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘，上海莱士报收于6.24元，上涨0.0%，换手率0.34%，成交量22.25万手，成交额1.39亿元。股本股东变化股东户数变动近日上海莱士披露，截至2026年2月27日公司股东户数为11.47万户，较2月13日增加440.0户，增幅为0.38%。户均持股数量由上期的5.81万股减少至5.79万股，户均持股市值为36.39万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100000565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0188","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618606233","title":"上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2618606233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618606233?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:48","pubTimestamp":1773103691,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)03月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司作为海尔集团的子公司，建议公司更名为上海海尔莱士血液制品股份有限公司，增加公司知名度。上海莱士回复：您好！感谢您对我公司的关心和建议！公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素。长期以来上海莱士品牌在行业内树立起了安全、优质的品牌形象，产品质量也获得了市场的信赖以及认可。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000005437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0046","002252","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413016","title":"上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413016","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618413016?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:14","pubTimestamp":1773047659,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)公告称，全资子公司同路生物制药有限公司收到内蒙古自治区卫生健康委员会下发的《内蒙古自治区卫生健康委关于同意设置丰镇市同路单采血浆站的批复》。近日，丰镇市同路单采血浆有限公司收到《单采血浆许可证》，业务项目包括机采单采普通原料血浆等，设置单采血浆站的血液制品生产单位为同路生物制药有限公司，采浆区域为丰镇市城内。该事项有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900023071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0196","BK0188","002252","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616533703","title":"上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616533703?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:15","pubTimestamp":1772615719,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：最近区域冲突不断，请问血制品对军方来说是否为强需求？上海莱士回复：您好！感谢您对我公司的关心和支持！血液制品在临床急救、重症救治等场景中，发挥着重要的临床支持作用，是保障患者生命安全的重要医疗资源之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400030072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002252","BK0188","BK0239","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616738768","title":"上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616738768","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616738768?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:28","pubTimestamp":1772443736,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年2月13日公司股东户数为11.43万户，较1月30日减少875.0户，减幅为0.76%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至2月13日，生物制品行业平均股东户数为3.46万户。从股价来看，2026年1月30日至2026年2月13日，上海莱士区间跌幅为0.64%，在此期间股东户数减少875.0户，减幅为0.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200025420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","002252","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608857421","title":"上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608857421?lang=zh_cn&edition=full","pubTime":"2026-02-02 18:02","pubTimestamp":1770026524,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，上海莱士报收于6.26元，较前一交易日下跌0.63%，最新总市值为415.54亿元。该股当日开盘6.3元，最高6.32元，最低6.25元，成交额达2.18亿元，换手率为0.52%。上海莱士血液制品股份有限公司于近日披露《2025年前三季度权益分派实施公告》。本次实际现金分红总额为100,504,214.14元，折算每10股现金红利为0.151407元。股权登记日为2026年2月9日，除权除息日为2026年2月10日。公司回购股份69,081,952股不参与本次分红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200027384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","002252","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607041663","title":"上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041663?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:30","pubTimestamp":1769783440,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，上海莱士报收于6.3元，较前一交易日下跌0.94%，最新总市值为418.19亿元。该股当日开盘6.34元，最高6.37元，最低6.27元，成交额达2.58亿元，换手率为0.62%。上海莱士近日披露公告显示，其全资子公司同路生物制药有限公司近日收到国家药品监督管理局签发的《药品注册证书》，药品名称为人纤维蛋白原，剂型为注射剂，注册分类为治疗用生物制品，适应症为先天性纤维蛋白原减少或缺乏症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0028","BK0239","BK0046","002252"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777338674066,"stockEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":-0.065},{"period":"3month","weight":-0.142},{"period":"6month","weight":-0.1816},{"period":"1year","weight":-0.1802},{"period":"ytd","weight":-0.1352}],"compareEarnings":[{"period":"1week","weight":0.001},{"period":"1month","weight":0.0441},{"period":"3month","weight":-0.0129},{"period":"6month","weight":0.0174},{"period":"1year","weight":0.2401},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"113602人(较上一季度增加0.00%)","perCapita":"58394股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"663798万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}